Description

(2S,4S)-Argatroban is a highly potent and selective direct thrombin inhibitor, representing a critical active pharmaceutical ingredient (API) in the pharmaceutical industry. Its primary value lies in its specific mechanism of action, which is essential for the development of anticoagulant therapies. This compound is of significant interest to pharmaceutical manufacturers and research institutions focused on cardiovascular medicine, particularly for the production of injectable antithrombotic drugs used to treat or prevent blood clots in conditions such as heparin-induced thrombocytopenia (HIT).

Application

• Pharmaceutical API: Primary use as the active ingredient in the manufacture of injectable anticoagulant medications.
• Antithrombotic Therapy: Formulation of drugs for the treatment and prevention of thrombosis in patients with heparin-induced thrombocytopenia (HIT) and other clotting disorders.
• Cardiovascular Research: A key reference standard and tool compound in biochemical and pharmacological studies of thrombin inhibition and blood coagulation pathways.
• Clinical Diagnostics: Potential use in the calibration of diagnostic assays that measure thrombin activity or anticoagulant efficacy.
• Drug Development: Serving as a lead compound or benchmark in the research and development of novel direct thrombin inhibitors.

Basic Information

Product Name	(2S,4S)-Argatroban
CAS No.	189264-03-7
Molecular Formula	C23H36N6O5S
Molecular Weight	508.64 g/mol
Synonyms	Argatroban; (2R,4R)-Argatroban (enantiomer); (2S,4S)-4-Methyl-1-[N2-((R,S)-3-methyl-1,2,3,4-tetrahydro-8-quinolinesulfonyl)-L-arginyl]-2-piperidinecarboxylic acid; MD-805; Novastan; Slonnon; 2-Piperidinecarboxylic acid, 4-methyl-1-[N2-((3-methyl-1,2,3,4-tetrahydro-8-quinolinyl)sulfonyl)-L-arginyl]-, (2S,4S)-; L-Arginine, N2-[(1,2,3,4-tetrahydro-3-methyl-8-quinolinyl)sulfonyl]-4-methyl-1-[4-methyl-1-oxo-2-[(2S,4S)-4-methyl-2-piperidinylcarbonyl]amino]pentyl]-, (S)-
EINECS	Contact for details

Quality Control

Our (2S,4S)-Argatroban is manufactured under strict quality management systems to ensure it meets the stringent requirements for pharmaceutical active ingredients. Each batch undergoes comprehensive analytical testing, including identity confirmation, purity assay, and impurity profiling via advanced techniques like HPLC and mass spectrometry. We provide Certificates of Analysis (COA) with each shipment, detailing all critical quality attributes. Production can be aligned with cGMP (current Good Manufacturing Practice) standards for drug substance manufacture upon request.

Storage

Preserve in a tightly closed container, protected from light. Store in a cool, dry place at a controlled room temperature (15-25°C). This material is hygroscopic (moisture-sensitive); the container must be kept tightly sealed in a dry environment to prevent degradation. For long-term storage, consider desiccants or inert atmosphere packaging.

Specification

Item	Specification
Appearance	White to off-white powder
Identification (IR)	Conforms to reference spectrum
Identification (HPLC)	Retention time corresponds to reference standard
Assay (HPLC)	≥ 98.0%
Specific Rotation	Contact for details
Related Substances (HPLC)	Total impurities ≤ 2.0% Any single unknown impurity ≤ 0.5%
Residual Solvents (GC)	Complies with ICH Q3C guidelines
Water Content (KF)	≤ 1.0%
Residue on Ignition	≤ 0.1%
Heavy Metals	≤ 20 ppm

Note: Specifications can be tailored. Please contact us for the detailed technical data sheet of a specific grade.